Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough blood cancers: early trial of LY4584180 begins

NCT ID NCT07226843

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 5 times

Summary

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 460 people will take part, and the study lasts around 9 months or longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 460 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: * Diffuse large B-cell lymphoma - not otherwise specified * High-grade B-cell lymphoma * Diffuse large B-cell lymphoma - transformed from indolent lymphomas * Follicular large B-cell lymphoma * Follicular lymphoma * Other non-Hodgkin lymphoma * Has measurable disease * Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy Exclusion Criteria: * Has an active second cancer * Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval. * Has known Cytomegalovirus infection. Participants with negative status are eligible * Has known hepatitis B or C infection or uncontrolled HIV * Has known significant heart disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Follicular lymphoma Lymphoma diffuse large B-cell Lymphoma, non-Hodgkin's

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    46 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIDPORT Sp. z o.o.

    NOT_YET_RECRUITING

    Skorzewo, 60-185, Poland

  • Baylor College of Medicine

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie

    NOT_YET_RECRUITING

    Pessac, 33604, France

  • CHU de Nantes - Hotel-Dieu

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Cancer Institute Hospital of JFCR

    NOT_YET_RECRUITING

    Tokyo, 135-8550, Japan

  • Charite Universitaetsmedizin Berlin

    NOT_YET_RECRUITING

    Berlin, 10117, Germany

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Columbia University

    RECRUITING

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Derriford Hospital

    NOT_YET_RECRUITING

    Plymouth, PL6 8DH, United Kingdom

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Florida Cancer Specialists - Sarasota

    RECRUITING

    Sarasota, Florida, 34236, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • HCL Centre Hospitalier Lyon Sud

    NOT_YET_RECRUITING

    Pierre-Bénite, 69495, France

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    NOT_YET_RECRUITING

    Bologna, 40138, Italy

  • Institut Catala d'Oncologia - L'Hospitalet

    NOT_YET_RECRUITING

    Barcelona, 08908, Spain

  • Institut Curie

    NOT_YET_RECRUITING

    Paris, 75005, France

  • Instytut Hematologii i Transfuzjologii w Warszawie

    NOT_YET_RECRUITING

    Warsaw, 02-776, Poland

  • Istituto Europeo di Oncologia

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • King's College Hospital

    NOT_YET_RECRUITING

    London, SE5 9RS, United Kingdom

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic - Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic - Scottsdale

    RECRUITING

    Scottsdale, Arizona, 85259, United States

  • National Cancer Center Hospital East

    NOT_YET_RECRUITING

    Chiba, 277-8577, Japan

  • Nottingham City Hospital

    NOT_YET_RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Okayama University Hospital

    NOT_YET_RECRUITING

    Okayama, 700-8558,, Japan

  • Oncopole Claudius Regaud

    NOT_YET_RECRUITING

    Toulouse, 31059, France

  • Oregon Health & Science University (OHSU)

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

  • Pratia MCM Krakow

    NOT_YET_RECRUITING

    Krakow, 30-727, Poland

  • Pratia Onkologia Katowice

    NOT_YET_RECRUITING

    Katowice, 40-519, Poland

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    NOT_YET_RECRUITING

    Madrid, 28040, Spain

  • Texas Oncology - DFW (Sammons CC)

    RECRUITING

    Dallas, Texas, 75246, United States

  • The Ohio State University (OSU)

    RECRUITING

    Columbus, Ohio, 43210, United States

  • The Royal Marsden NHS Foundation Trust

    NOT_YET_RECRUITING

    London, SW3 6JJ, United Kingdom

  • Universitaetsklinikum Essen

    NOT_YET_RECRUITING

    Essen, 45147, Germany

  • Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet

    NOT_YET_RECRUITING

    Frankfurt am Main, 60590, Germany

  • Universitaetsklinikum Koeln (AoeR)

    NOT_YET_RECRUITING

    Cologne, 50937, Germany

  • University Hospital Southampton NHS Foundation Trust

    NOT_YET_RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • University of California, Los Angeles (UCLA) - Medical Center

    RECRUITING

    Los Angeles, California, 90059, United States

  • University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

    NOT_YET_RECRUITING

    San Francisco, California, 94158, United States

  • University of Miami - Sylvester Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Rochester

    RECRUITING

    Rochester, New York, 14618, United States

  • University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)

    RECRUITING

    Seattle, Washington, 98195, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.